{"id":37632,"date":"2026-11-17T20:24:37","date_gmt":"2026-11-17T18:24:37","guid":{"rendered":"https:\/\/ukrmedia.news\/?p=37632"},"modified":"2026-11-17T20:24:37","modified_gmt":"2026-11-17T18:24:37","slug":"fda-approves-neladalkib-lung-cancer","status":"publish","type":"post","link":"https:\/\/ukrmedia.news\/en\/science-tech\/fda-approves-neladalkib-lung-cancer\/","title":{"rendered":"A new lung cancer drug has been approved in the US: who is Nelkarmi intended for?"},"content":{"rendered":"<p>On 17 November 2026, the US Food and Drug Administration (FDA) granted accelerated approval to the drug neladalkib, which will be marketed under the brand name Nelkarmi. The medicine, developed by the British pharmaceutical company GSK, is intended for patients with advanced ALK-positive non-small cell lung cancer whose disease has progressed following prior treatment with ALK tyrosine kinase inhibitors.<\/p>\n<div>\n<div>\n<h2>For which patients has the new medicine been approved?<\/h2>\n<p>Neladalkib is designed to treat ALK-positive non-small cell lung cancer (NSCLC). This is a type of cancer in which genetic changes associated with the ALK gene occur in the tumour cells.<\/p>\n<p>Such changes could lead to uncontrolled reproduction <a href=\"https:\/\/ukrmedia.news\/en\/science-tech\/anthropic-ai-likuvannya-raku-10-rokiv\/\">cancer cells<\/a>. Therefore, special drugs that block the activity of the relevant protein are used for treatment.<\/p>\n<p>However, over time, the tumour may become resistant to treatment. In such cases, the disease progresses again, and the options for further treatment become more limited.<\/p>\n<p>The new drug belongs to the class of ALK inhibitors and is designed to target tumour cells, particularly once resistance to previous treatments has developed.<\/p>\n<p>However, Nelkarmi is not indicated for all types of lung cancer. Its use depends on the molecular characteristics of the tumour, previous treatment and the patient\u2019s clinical condition.<\/p>\n<h2>What results did neladalkib show in clinical trials?<\/h2>\n<p>The basis for the evaluation of the medicinal product was the results of the international Phase I and II ALKOVE-1 clinical trial.<\/p>\n<p>The study assessed the efficacy and safety of neladalkib in patients with advanced ALK-positive lung cancer, particularly following prior targeted therapy.<\/p>\n<p>According to the published results, among the 253 patients who had previously received ALK inhibitors, an objective tumour response to treatment was observed in 31 per cent.<\/p>\n<p>An objective response means that the tumour has shrunk in accordance with the established assessment criteria. This indicator does not imply a complete cure or a guaranteed increase in life expectancy.<\/p>\n<p>Among patients who had previously received lorlatinib, the response rate was approximately 26 per cent. The researchers also assessed the drug\u2019s efficacy against tumours in the central nervous system.<\/p>\n<p>According to the ALKOVE-1 study, in a group of 92 patients with measurable central nervous system lesions, an intracranial response was observed in 32 per cent.<\/p>\n<h2>What side effects were observed during the trials?<\/h2>\n<p>During the study, the researchers also assessed the tolerability of neladalkib.<\/p>\n<p>Common adverse reactions reported included elevated liver enzyme levels, constipation, changes in taste perception, oedema, cough and nausea.<\/p>\n<p>According to previously published data from the ALKOVE-1 trial, approximately 17 per cent of participants required a reduction in their dose due to adverse reactions, whilst around 5 per cent discontinued treatment.<\/p>\n<p>These figures relate to the study group and do not imply that the risk of side effects will be the same for all patients.<\/p>\n<p>The choice of treatment should be made by an oncologist, taking into account previous treatment and the molecular profile <a href=\"https:\/\/ukrmedia.news\/en\/science-tech\/avstraliyets-stvoryv-vaktsynu-vid-raku\/\">tumours<\/a>, possible interactions with other medicines and contraindications.<\/p>\n<h2>What does \u2018accelerated approval\u2019 by the FDA mean?<\/h2>\n<p>Accelerated Approval allows patients to gain earlier access to promising medicines for serious diseases, provided that preliminary trial results indicate a potential clinical benefit.<\/p>\n<p>However, this does not mean that the drug\u2019s efficacy has already been definitively confirmed across all clinical indicators.<\/p>\n<p>The manufacturer must carry out further studies to demonstrate the actual benefits to patients. If the expected effect is not confirmed, the FDA may review or revoke the authorisation.<\/p>\n<h2>GSK is expanding its portfolio of lung cancer medicines<\/h2>\n<p>Neladalkib became part of GSK\u2019s portfolio following the acquisition of the US biotechnology company Nuvalent for $10.6 billion in 2026.<\/p>\n<p>Under this agreement, GSK has acquired two promising drugs targeting different molecular subtypes of non-small cell lung cancer \u2014 neladalkib and zidesamtinib.<\/p>\n<p>The latter, which is used to treat ROS1-positive lung cancer, was approved by the US regulatory authority on 22 July 2026.<\/p>\n<p>This new approval broadens the treatment options for patients with ALK-positive lung cancer for whom previous targeted therapy has proved insufficiently effective.<\/p>\n<p>As of 17 November, the FDA had granted accelerated approval to Nelkarmi in the US. Further studies are required to confirm the drug\u2019s long-term clinical benefits. There is currently no information regarding its registration in Ukraine.<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>\u0423\u043f\u0440\u0430\u0432\u043b\u0456\u043d\u043d\u044f \u0437 \u043a\u043e\u043d\u0442\u0440\u043e\u043b\u044e \u0437\u0430 \u043f\u0440\u043e\u0434\u0443\u043a\u0442\u0430\u043c\u0438 \u0439 \u043b\u0456\u043a\u0430\u043c\u0438 \u0421\u0428\u0410 (FDA) 17 \u043b\u0438\u0441\u0442\u043e\u043f\u0430\u0434\u0430 2026 \u0440\u043e\u043a\u0443 \u043d\u0430\u0434\u0430\u043b\u043e \u043f\u0440\u0438\u0441\u043a\u043e\u0440\u0435\u043d\u0435 \u0441\u0445\u0432\u0430\u043b\u0435\u043d\u043d\u044f \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0443 neladalkib, \u044f\u043a\u0438\u0439 \u043f\u0440\u043e\u0434\u0430\u0432\u0430\u0442\u0438\u043c\u0443\u0442\u044c \u043f\u0456\u0434 \u0442\u043e\u0440\u0433\u043e\u0432\u0435\u043b\u044c\u043d\u043e\u044e \u043d\u0430\u0437\u0432\u043e\u044e Nelkarmi. \u041b\u0456\u043a\u0438 \u0431\u0440\u0438\u0442\u0430\u043d\u0441\u044c\u043a\u043e\u0457 \u0444\u0430\u0440\u043c\u0430\u0446\u0435\u0432\u0442\u0438\u0447\u043d\u043e\u0457 \u043a\u043e\u043c\u043f\u0430\u043d\u0456\u0457 GSK \u043f\u0440\u0438\u0437\u043d\u0430\u0447\u0435\u043d\u0456 \u0434\u043b\u044f \u043f\u0430\u0446\u0456\u0454\u043d\u0442\u0456\u0432 \u0456\u0437 \u043f\u0440\u043e\u0433\u0440\u0435\u0441\u0443\u044e\u0447\u0438\u043c ALK-\u043f\u043e\u0437\u0438\u0442\u0438\u0432\u043d\u0438\u043c \u043d\u0435\u0434\u0440\u0456\u0431\u043d\u043e\u043a\u043b\u0456\u0442\u0438\u043d\u043d\u0438\u043c \u0440\u0430\u043a\u043e\u043c \u043b\u0435\u0433\u0435\u043d\u044c, \u0443 \u044f\u043a\u0438\u0445 \u0437\u0430\u0445\u0432\u043e\u0440\u044e\u0432\u0430\u043d\u043d\u044f \u043f\u0440\u043e\u0434\u043e\u0432\u0436\u0438\u043b\u043e \u0440\u043e\u0437\u0432\u0438\u0432\u0430\u0442\u0438\u0441\u044f \u043f\u0456\u0441\u043b\u044f \u043f\u043e\u043f\u0435\u0440\u0435\u0434\u043d\u044c\u043e\u0433\u043e \u043b\u0456\u043a\u0443\u0432\u0430\u043d\u043d\u044f \u0456\u043d\u0433\u0456\u0431\u0456\u0442\u043e\u0440\u0430\u043c\u0438 \u0442\u0438\u0440\u043e\u0437\u0438\u043d\u043a\u0456\u043d\u0430\u0437\u0438 ALK. \u0414\u043b\u044f \u044f\u043a\u0438\u0445 \u043f\u0430\u0446\u0456\u0454\u043d\u0442\u0456\u0432 \u0441\u0445\u0432\u0430\u043b\u0438\u043b\u0438 \u043d\u043e\u0432\u0438\u0439 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442 [\u2026]<\/p>\n","protected":false},"author":207433355,"featured_media":37633,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rank_math_description":"FDA \u0441\u0445\u0432\u0430\u043b\u0438\u043b\u043e \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442 Nelkarmi \u0432\u0456\u0434 GSK \u0434\u043b\u044f \u043f\u0430\u0446\u0456\u0454\u043d\u0442\u0456\u0432 \u0456\u0437 ALK-\u043f\u043e\u0437\u0438\u0442\u0438\u0432\u043d\u0438\u043c \u0440\u0430\u043a\u043e\u043c \u043b\u0435\u0433\u0435\u043d\u044c \u043f\u0456\u0441\u043b\u044f \u043f\u043e\u043f\u0435\u0440\u0435\u0434\u043d\u044c\u043e\u0457 \u0442\u0435\u0440\u0430\u043f\u0456\u0457. \u0429\u043e \u043f\u043e\u043a\u0430\u0437\u0430\u043b\u0438 \u0434\u043e\u0441\u043b\u0456\u0434\u0436\u0435\u043d\u043d\u044f?","rank_math_title":"FDA \u0434\u043e\u0437\u0432\u043e\u043b\u0438\u043b\u043e \u043d\u043e\u0432\u0456 \u043b\u0456\u043a\u0438 \u0434\u043b\u044f \u043f\u0430\u0446\u0456\u0454\u043d\u0442\u0456\u0432 \u0456\u0437 \u0440\u0456\u0434\u043a\u0456\u0441\u043d\u043e\u044e \u0444\u043e\u0440\u043c\u043e\u044e \u0440\u0430\u043a\u0443 \u043b\u0435\u0433\u0435\u043d\u044c","rank_math_focus_keyword":"FDA","td_subtitle":"","subtitle":"","footnotes":""},"categories":[805620],"tags":[806790],"class_list":["post-37632","post","type-post","status-publish","format-standard","has-post-thumbnail","category-science-tech","tag-806790"],"_links":{"self":[{"href":"https:\/\/ukrmedia.news\/en\/wp-json\/wp\/v2\/posts\/37632","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ukrmedia.news\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ukrmedia.news\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ukrmedia.news\/en\/wp-json\/wp\/v2\/users\/207433355"}],"replies":[{"embeddable":true,"href":"https:\/\/ukrmedia.news\/en\/wp-json\/wp\/v2\/comments?post=37632"}],"version-history":[{"count":1,"href":"https:\/\/ukrmedia.news\/en\/wp-json\/wp\/v2\/posts\/37632\/revisions"}],"predecessor-version":[{"id":37634,"href":"https:\/\/ukrmedia.news\/en\/wp-json\/wp\/v2\/posts\/37632\/revisions\/37634"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ukrmedia.news\/en\/wp-json\/wp\/v2\/media\/37633"}],"wp:attachment":[{"href":"https:\/\/ukrmedia.news\/en\/wp-json\/wp\/v2\/media?parent=37632"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ukrmedia.news\/en\/wp-json\/wp\/v2\/categories?post=37632"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ukrmedia.news\/en\/wp-json\/wp\/v2\/tags?post=37632"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}